Vertex Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Vertex (VRTX) Q1 Quiet, But Reimbursement Commentary 'Encouraging'; Leerink Says; PT Up to $150
April 30, 2015 6:18 AM EDTLeerink Partners analyst Howard Liang reiterated an Outperform rating and boosted his price target on Vertex (NASDAQ: VRTX) to $150.00 (from $131.00) following a "quiet" quarter as reimbursement commentary was encouraging.
Liang commented, "VRTX reported roughly in-line Kalydeco sales for 1Q:15 ($130M vs. our/consensus estimates of $127M/$131M).... More
Vertex Pharma (VRTX) Tops Q1 EPS by 13c
April 29, 2015 4:03 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q1 EPS of ($0.62), $0.13 better than the analyst estimate of ($0.75). Revenue for the quarter came in at $138.5 million versus the consensus estimate of $142.38 million.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
... More